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Current scaffold-based tissue engineering approaches are subject to several limitations, such 
as design inflexibility, poor cytocompatibility, toxicity, and post-transplant degradation. Thus, 
scaffold-free tissue-engineered structures could be a promising solution to overcome the 
issues associated with classical scaffold-based materials in clinical transplantation. The 
present study seeks to optimize the culture conditions and cell combinations used to generate 
scaffold-free structures using a bio-3D printing system. Human cartilage cells, human 
fibroblasts, human umbilical vein endothelial cells, and human mesenchymal stem cells from 
bone marrow were aggregated into spheroids and placed into a bio-3D printing system with 
dedicated needles positioned according to 3D configuration data to develop scaffold-free 
trachea-like tubes. Culturing the bio-3D-printed structures with proper flow of specific 




physical strength and tissue function. The bio-3D-printed tissue formed small-diameter 
trachea-like tubes that are implanted into rats with the support of catheters. It is confirmed 
that the tubes are viable in vivo and that the tracheal epithelium and capillaries proliferated. 
This tissue-engineered, scaffold-free, tubular structure can represent a significant step towards 




The trachea is essential for respiration, phonation, and airway protection. Thus, if it narrows 
or collapses, it is life-threatening.[1–3] Safe, resectable tracheal ranges are approximately half 
the length in adults and one third the length in children.[4,5] A variety of tracheal replacement 
strategies have been reported, including artificial prostheses,[6,7] autografts,[8] native or 
decellularized allografts,[9] and autologous grafts of tissue-engineered constructs.[10–12] 
However, all these methods have shortcomings. Acellular tracheal prostheses often cause 
tissue granulation, implant migration, progressive scar formation, and restenosis.[13] 
Autografts and allografts undergo remodeling upon implantation, due to their limited 
availability and poor mechanical properties, this leads to collapse, scarring, and airway 
occlusion. [4] The use of allogeneic donor tissues can cause disease transmission and 
immunogenicity. Immune response issues can be avoided using tissue-engineered constructs 
comprising autologous cells in scaffolds, but the scaffolds lack design flexibility and the 
cytocompatibility of natural materials and may trigger a host response to toxic byproducts 
released during their degradation.[14] Thus, new techniques for producing scaffold-free tissue-
engineered constructs are required. 
One of our coauthors (K. Nakayama) developed a novel, robotic bio-3D printing system, 
“Regenova,” which allows to produce 3D cellular structures using multicellular spheroids in 




vessel-like structures, but they are physiologically distinct from other organs.[16] The vessels 
obtained oxygen and nutrients via blood flow through the structure interior, while other 
tubular organs generate their own blood vessels after in vivo implantation. Different 
approaches are necessary to create viable tubular organs. Therefore, we focused on the fact 
that support cells, such as fibroblasts[17] or mesenchymal stem cells[18,19], induce endothelial 
cells to form capillary-like structures in 3D co-cultures. Using a similar method, our coauthors 
successfully performed the autologous transplant of neo-cartilage structures made of primary 
cultured cells to rat cervical tracheas.[20] 
In this study, we attempted to generate neo-cartilaginous tubes and neo-fibrous tubes by co-
culture of human chondrocytes, human mesenchymal stem cells (MSCs), human fibroblasts, 
and human umbilical vein endothelial cells (HUVECs) using previously reported methods.[20] 
Additionally, we attempted to build a structure more similar to that of the native trachea with 
strength suitable for rat transplant. 
 
2. Results 
2.1 Cartilaginous tubes 
2.1.1 Gross morphological assessment and biomechanical analysis of cartilaginous tubes 
Cartilaginous tubes were formed by 7 groups of spheroids. Group C-I consisted exclusively of 
normal human articular chondrocytes (NHACs). Group C-II consisted of NHACs and 
HUVECs. Group C-III consisted of NHACs, HUVECs, and MSCs; this group was further 
divided into groups C-IIIa, C-IIIb, and C-IIIc each containing a different ratio of NHACs and 
MSCs. Group C-IV consisted of HUVECs and MSCs. Group C-V consisted exclusively of 
MSCs (see Table S1 for details). The structures in groups C-I and C-V were weaker and more 
difficult to handle than those of other groups, owing to their thinness (Figure 1a–g). The 
thickness and length of the structures at the time of bio-3D printing were approximately 550 




different groups were: C-I, 0.56 ± 0.09 mm; C-II, 0.75 ± 0.06 mm; C-IIIa, 0.60 ± 0.16 
mm; C-IIIb, 0.86 ± 0.03 mm; C-IIIc, 0.76 ± 0.25 mm; C-IV, 0.81 ± 0.07 mm; C-V, 0.69 
± 0.16 mm. There were no significant differences between the thicknesses values among the 
groups (Figure 1h).  
The lengths of the different groups were: C-I, 4.37 ± 1.19 mm; C-II, 3.15 ± 1.65 mm; C-IIIa, 
2.96 ± 0.30 mm; C-IIIb, 1.95 ± 0.41 mm; C-IIIc, 2.17 ± 0.17 mm; C-IV, 1.54 ± 0.27 mm; 
C-V, 1.81 ± 0.70 mm. The thickness and length of group C-I remained unchanged after 35 
days of culture. However, as the proportion of MSCs in the structures exceeded 40%, the 
lengths tended to shorten significantly (Figure 1i). 
The force at failure and ultimate tensile strength (UTS) of the different groups were: C-I, 
92.25 ± 77.22 mN and 38.78 ± 29.69 kPa; C-II, 420.66 ± 151.45 mN and 190.96 ± 67.35 
kPa; C-IIIa, 460.50 ± 294.05 mN and 290.63 ± 164.62 kPa; C-IIIb, 283.20 ± 95.27 mN 
and 188.58 ± 74.20 kPa; C-IIIc, 294.67 ± 159.72 mN and 207.64 ± 107.11 kPa; C-IV, 
158.00 ± 134.95 mN and 107.75 ± 87.56 kPa; C-V, 27.33 ± 22.01 mN and 21.86 ± 15.28 
kPa. Group C-IIIa exhibited a significantly higher force at failure and UTS compared to other 
groups (Figure 1j, k). The structures printed from spheroids of NHACs and MSCs collapsed 
during culture and were not evaluated (data not shown).  
 
2.1.2 Biochemical analysis of cartilaginous tubes 
Glycosaminoglycan (GAG) content and GAG content normalized to DNA content of the 
different groups were: C-I, 37.05 ± 7.30 μg/ml and 49.72 ± 13.88 μg/μg; C-II, 30.45 ± 
1.80 μg/ml and 74.05 ± 18.99 μg/μg; C-IIIa, 29.45 ± 5.00 μg/ml and 86.04 ± 17.67 μg/μg; 
C-IIIb, 35.06 ± 5.89 μg/ml and 70.04 ± 20.51 μg/μg; C-IIIc, 30.05 ± 3.08 μg/ml and 78.88 




μg/ml and 62.29 ±24.31 μg/μg. Groups C-IV and C-V that did not include NHACs had lower 
GAG and DNA content (an indirect measure of cell number) than the other groups (Figure 1l, 
m). The groups that included NHACs showed no significant difference in GAG content or 
GAG/DNA among them (Figure 1l, n).  
 
2.1.3 Histology and immunohistochemistry of cartilaginous tubes 
Although NHACs were not included in groups C-IV and C-V, deposition of GAG was 
detected in all groups by Alcian blue staining (Figure 2a, e, I, m, q, u, y). Similarly, collagen 
II was detected in all groups (Figure 2b, f, j, n, r, v, z). However, the area of collagen II 
detection was narrower in group C-V than in the other groups (Figure 2b, f, j, n, r, v, z). 
Collagen IV was not detected in group C-V (Figure 2aa), while the groups that included 
HUVECs had the same amount at the time of bio-3D printing, positive cells for the 
endothelial marker cluster of differentiation (CD) 31 (CD31+ cells) were broadly detected in 
groups C-IIIa, C-IIIb, and C-IIIc; and only slightly detected in groups C-II and C-IV(Figure 
2d, h, l, p, t, x, bb).  
 
2.2 Fibrous tubes 
2.2.1 Gross morphological assessment and biomechanical analysis of fibrous tubes 
Fibrous tubes were formed by 4 spheroid groups. Group F-I consisted exclusively of normal 
human dermal fibroblasts (NHDFs). Group F-II consisted of NHDFs and HUVECs. Group F-
III consisted of NHDFs and MSCs. Group F-IV consisted of NHDFs, HUVECs, and MSCs 
(see Table S1 for details). The thickness and length of the structures at the time of bio-3D 
printing were approximately 550 µm and 5 mm, respectively, in all groups. After 35 days of 
culture, the thickness and length of the different groups were: F-I, 0.81 ± 0.04 mm and 3.27 




0.25 mm; F-IV, 0.85 ± 0.16 mm and 3.51 ± 0.57 mm. The values were similar across the 4 
groups (Figure 3e, f). The force at failure and UTS of the different groups were: F-I, 209.33 
± 45.65 mN and 77.67 ± 3.30 kPa; F-II, 201.50 ± 103.32 mN and 101.35 ± 60.76 kPa; F-
III, 218.80 ± 65.67 mN and 79.32 ± 24.22 kPa; F-IV, 448 ± 32.04 mN and 155.99 ±33.06 
kPa. Mechanical analysis of the uniaxial tension revealed that the force at failure depended on 
the cell combination used to generate the spheroids. For instance, group F-IV exhibited a 
tensile strength significantly higher than that of other groups (Figure 3g). A similar 
phenomenon was observed for the UTS (Figure 3h). 
 
2.2.2 Histology and immunohistochemistry of fibrous tubes 
Masson’s trichrome staining showed abundant and thick collagenous fiber bundles in the 
outer layers of the structures (Figure 4a, f, k, p) and a pronounced collagen deposition was 
observed in the outer layers of all groups upon Fast Green/Picrosirius Red staining (Figure 4b, 
g, l, q). Polarized light microscopy showed that the collagenous fiber bundles mostly 
consisted of large collagen fibers and that the fiber bundles in group F-IV were broader and 
longer than those of other groups (Figure 4c, h, m, r). Collagen IV was detected in the central 
areas of all structures (Figure 4d, I, n, s). CD31 was detected in the central regions of group 
F-II structures and throughout F-IV structures (Figure 4e, j, o, t). Furthermore, small luminal 
CD31+ cell aggregates were observed in group F-IV but not in group F-III structures (Figure 
4j, t).  
 
2.3 Trachea-like tubes 
2.3.1 Gross morphological assessment and biomechanical analysis of trachea-like tubes 
Immediately after bio-3D printing, the spheroids of group F-IV were indistinguishable from 




forming laminar structures of F-IV and C-IIIa rings (Figure 5b; with Kenzan, Figure 5c; 
without Kenzan, F-IV ring, orange; C-IIIa ring, yellowish-white). However, after 35 days of 
culture, the trachea-like tubes lost its laminar appearance and acquired an orange coloration 
(Figure 5d).  
The thickness and length of the trachea-like tubes harvested after 35 days of culture were 0.81 
± 0.23 mm and 3.79 ± 1.11 mm, similar to those of the fibrous tubes (group F-IV) and 
higher than those of cartilaginous tubes (group C-IIIa) and native rat tracheas (0.40 ± 0.08 
mm thick and 2.35 ± 0.25 mm long)(Figure 5e, f). The UTS of the trachea-like tubes was 
258.23 ± 173.60 kPa, significantly less than that of native rat tracheas (878.44 ± 137.15 
kPa)(Figure 5h). However, their force at failure was 683.0 ± 259.32 mN, showing no 
significant difference to that of native rat tracheas, but significantly higher than that of the 
cartilaginous and fibrous tubes (Figure 5g).  
 
2.3.2 Biochemical analysis of trachea-like tubes 
GAG content in the trachea-like tubes was 50.93 ± 9.12 μg/ml, significantly higher than that 
in the fibrous and cartilaginous tubes; however, the GAG content of native rat tracheas was 
101.39 ± 8.37 μg/ml, much higher than that of the trachea-like tubes (Figure 5i). In contrast, 
DNA, an indirect measure of cell number, was significantly more abundant in the trachea-like 
tubes than in the cartilaginous tubes and the native rat tracheas (Figure 5j). GAG content 
normalized to DNA content in the trachea-like tubes was 43.1 ± 11.07 μg/μg, significantly 
lower than in cartilaginous tubes and native rat tracheas (Figure 5k). 
 
2.3.3 Histology and immunohistochemistry of trachea-like tubes 
Trachea-like tubes harvested after 35 days of culture were subjected to various stains. 




aligned with the outer structure layer, but apparently did not align with the inner layer, where 
cell density was lower (Figure 6a). The laminar appearance of the trachea-like tubes might 
become incomprehensible because of this phenomenon. Extensive extracellular matrix (ECM) 
production was observed throughout the structures by Masson’s trichrome staining (Figure 
6b). Although the trachea-like tubes consisted of alternating F-IV and C-IIIa rings, Alcian 
blue staining was detected evenly inside the structures, and the differences between F-IV and 
C-IIIa rings were undetectable (Figure 6c). Similarly, collagen II and IV were equally 
identified inside the structure (Figure 6d, e). In contrast, small luminal CD31+ cell aggregates 
were observed only in F-IV ring areas, although C-IIIa rings also contained HUVECs (Figure 
6f, g). 
 
2.3.4 Remodeling of the trachea-like tubes after transplantation 
Seven days after transplantation the surfaces of the trachea-like tubes were covered in 
granulation tissue with small blood vessels, and their borders with the native rat tracheas were 
indistinguishable (Figure 7c). In contrast, 35 days after transplantation, the structures had 
shrunk, and the granulation tissue was less apparent (Figure 7d).  
Seven days after transplantation, the trachea-like tubes had small luminal CD31+ cell 
aggregates (Figure 7f) and 35 days after transplantation, the CD31+ cells surrounded a larger 
lumen (Figure 7k). The presence of pan-cytokeratin positive epithelial cells on the luminal 
side of the trachea-like tubes was confirmed 35 (Figure 7l) but not 7 days after 
transplantation (Figure 7g). Epithelial cells were not included in the spheroids, so these cells 
probably migrated from the native rat tracheas. Alcian blue (Figure 7h, m) and collagen II 
(Figure 7i, n) staining became more evident in the trachea-like tubes over time. 
 





The trachea is formed by various cells types and tissues that provide its specific functions.[21] 
Many trachea regeneration trials have been reported; however, most required scaffolds. The 
use of scaffolds in the airway produces negative effects after in vivo transplantation.[22,23] 
Therefore, artificial tracheas without scaffolds are preferred. Several methods have been 
previously reported to generate tubular structures from cells. For instance, scaffold-free 
tissue-engineered blood vessels have been generated by cell sheet engineering. However, 
these approaches require repeated attempts and culture times of nearly 6 months before 
transplantation.[24] Similarly, other studies have attempted to use multicellular spheroids to 
generate scaffold-free tubular structures; however, these studies used molds to fuse spheroids 
and were thus limited to structures with specific shapes.[23,25,26] 
We previously reported the convenience of scaffold-free isogenic artificial tracheas produced 
by the bio-3D printing system in rats.[20] This previous report showed the potential of 
scaffold-free organs for clinical applications. However, the quality, strength, and maturation 
of bio-3D-printed scaffold-free structures vary according to cell source, species, and animal 
age.[16,20,27] Thus, it is necessary to investigate the quality and combination of the cells as well 
as the human cell and tissue culture conditions for clinical applications.  
In this study, we investigated the function of artificial tracheas made with human cells. We 
found that spheroids consisting of fibroblasts, HUVECs, and MSCs contributed to the 
flexibility and bloodstream of the structures, while spheroids composed of chondrocytes, 
HUVECs, and MSCs added to their rigidity. Combinations of the two spheroid types 
produced artificial tracheas with properties more similar to the native ones. Furthermore, the 
artificial tracheas functioned under immunosuppressive treatment for an extended period after 
transplantation procedures to replace sections of native tracheas in rats. Epithelium extension 
from the native tracheas and blood vessel connections between microvessels of neighbor 




During transplantation, the structure was strong enough to be sutured, but failed to maintain 
its shape after enduring continuous breathing for extended time periods, increasing mortality 
risk. Silicone stents were used to prevent collapse after transplantation, as described 
previously.[20] It took sufficient time for the surrounding tissues to connect to the transplanted 
artificial tracheas by appropriate vasculogenesis. In this study, we did not remove the stents 
after maturation of the artificial tracheas to avoid mortality risk in the rats, and we intend to 
focus on this issue in future works. Granulation, an adverse effect of stent use, was observed 
only slightly in this study, even though epithelial cells did not completely cover the inner 
surface of the lumen. This may be owing to the fact that our procedure was different from that 
of autologous transplantation, the fact that artificial and native tracheas were from different 
species, or immunosuppressant effects.[28]  
In the present study, three structures were evaluated according to mechanical strength and 
histological findings in vitro to choose the most appropriate for transplantation in rats. A 
cartilaginous tube, a fibrous tube, and a trachea-like tube that imitated 4 rings of the 
cartilaginous and fibroblast cell-based structures. The trachea-like tubes had the highest 
tensile strength, though the difference was not significant. Furthermore, although the GAG 
/DNA production of the trachea-like tubes was less than that of the cartilaginous tubes, the 
GAG production by the whole trachea-like tubes was greater. Because the strength of the 
entire structure was the most important aspect, the trachea-like tubes were chosen for 
transplantation.  
The trachea-like tubes were weaker than native tracheas of 9-week-old rats; however, we 
expected that the structures would gain strength after in vivo maturation supported by a 
stent.[20] The trachea-like tubes were probably stronger than the cartilaginous and fibrous 
tubes because of growth factor production by fibroblasts, ECM production by cartilaginous 




cell types should be stronger. however, such complex structures were not examined in the 
present study; we will investigate them in the future. 
In vivo maturation of the structures requires neovascularization, connecting microvessels in 
the structures, and native vasculature after transplantation.[20] In the present study, some 
lumens contained CD31+ cells 7 days after transplantation, and the cells surrounded a larger 
lumen after 35 days. To aid vascularization in vivo, HUVECs were included in both structures, 
these cells formed microvascular networks containing CD31+ cells in vitro and displayed 
many small vessel-like luminal structures. This inclusion may have positively affected the 
tensile strength of the structures because of ECM production. Blood vessel connections 
between microvessels in the structures and native vessels in the neighboring tissue were 
confirmed. The structures consisting human cells formed connections between their own 
vascular networks and those of the rat tissues around the tracheas, as observed in 
autografts.[20] Thus, the connection of the vasculature can occur even in tissues of different 
species, and HUVECs could become a cell source for vascularization of these 3D structures.  
Cartilaginification of the structures after transplantation did not occur in the present study as it 
did in previous reports[20] where cartilage was observed in the structures 23 days after 
transplantation. This may have been because the human chondrocytes used in this study were 
not primary cultured chondrocytes but had a partial fibroblast character because of rapid 
dedifferentiation during monolayer culture, resulting in a fibroblast-like phenotype that 
produced less cartilage than primary cells.[30] A previous study reported that aortic allografts 
with MSCs were transplanted to rabbit cervical tracheas supported with silicone stents. 
Fifteen months after transplantation, cartilaginous rings were confirmed around the grafts.[31] 
Thus, longer-term culture in the in vivo environment may be required for cartilage maturation. 
Nevertheless, our Bio-3D printing system produced trachea-like tubes without differentiation 




Our data show that the cartilaginous tube consisting of only chondrocytes (group C-I tubes) 
was too weak for transplantation. Therefore, other cell types were needed to strengthen the 
structures. One promising cell source was MSCs. However, a significant drawback is that 
these cells produce cartilage after chondrogenic induction which can lead to further 
hypertrophy and calcification. Additionally, they are expensive.[32] Recent studies have 
demonstrated that co-culture of articular chondrocytes (ACs) and MSCs mitigates these 
problems, as interactions between them maintain their chondrogenic phenotypes, resulting in 
robust chondrogenesis and minimized need for mature chondrocytes.[33–35] Additionally, 
although induction medium commonly supplemented with known chondrogenic factors, such 
as Transforming Growth Factor (TGF)- β, is usually needed for MSC differentiation to 
chondrocytes, co-culture with ACs in 3D conditions did not require these factors.[36, 37] In the 
3D conditions of our study, collagen II and GAG production were confirmed in the group C-
V tubes, suggesting chondrocytic differentiation of MSCs without supplements. However, the 
structures in this group were small, and their tensile strength was low. Only groups C-IV and 
C-V showed significant differences in GAG content among the chondrocyte groups, although 
the content ratio of chondrocyte cells was inverted. The spheroids consisting of only NHACs 
and MSCs were unable to maintain tubular structures for a long time after 3D printing. 
Therefore, it was suggested that MSCs should be used instead of NHACs and that HUVECs 
could promote effective chondrocytic differentiation of MSCs. We used a cell source ratio of 
7:2:1 of chondrocytes:HUVECs:MSCs for the cartilage rings in the trachea-like tubes because 
the tensile strength of group C-IIIa tubes was higher than that of the other groups, and its 
GAG content and GAG/DNA content were similar to that of any group besides C-IV and C-V. 
The cell source ratio of the fibrous membrane matched that of the cartilage rings. 
Regarding the distribution of ECM in the cartilaginous tube, collagen IV accumulated in the 
central area in all groups except group C-V, suggesting that adhesion between the ECM and 




strength of the structures because collagen IV increases structural integrity, stability, and 
function.[38] Furthermore, collagen IV, present in the central area, forms an insoluble network 
that plays a structural role in the basement membrane [39] that may be necessary for 
epithelialization of the cylindrical structures after implantation. 
A similar analysis was carried out to determine the cell combination for the fibrous tubes 
whose tensile strength depended on the cell types and ratios in the spheroids. Several reports 
indicated that the proliferation and differentiation of cell-derived tissue in 3D culture vary 
based on cell content. In fibroblast/HUVEC co-cultures, fibroblasts presence decreased the 
apoptosis level of endothelial cells[40] and generated an ECM, essential for luminal 
differentiation,[17] whereas HUVECs formed multi-cell microvessels in spheroids.[41] In 
MSC/fibroblast co-cultures, MSCs promoted fibroblast proliferation and pro-collagen 
production,[42] whereas endothelial cells regulated the MSC activity,[43] migration,[44] and 
differentiation,[18] required to stabilize newly formed vasculature. Group F-IV tubes had 
broader and longer fiber bundles than the other groups. As a result, the structure consisting of 
fibroblasts, HUVECs, and MSCs had the highest mechanical strength and was chosen for the 
fibrous ring.  
The Bio-3D printing system used in the present study provides several benefits, including 
compatibility with multiple spheroid types, ability to generate various 3D forms, and enough 
medium circulation around the assembled spheroids to support the cells until tissue 
maturation. Compared to the conventional forms of 3D printing, our method has two 
particular advantages. First, the Bio-3D printer can be used to make structures without folds, 
and, second, the structures generated by this technique develop sufficient strength within a 
month. Despite these advantages, the molecular mechanisms underlying the pattern and 
distribution of ECM proteins require further investigation.  
The present study has some limitations. First, although the fabricated tubes were small (4 mm 




model, like human tracheas, would require significantly more cells and a longer culture period. 
Further studies must be conducted using mass culture and larger spheroids to decrease the 
printing time. Second, the structures were observed for only one month in vitro and in vivo. 
Third, several other primary cell types, including smooth muscle cells, and their combination 
in different ratios, may have improved the structures but were not investigated. Finally, the 
strength of the trachea-like tubes was lower than that of the native trachea. To overcome this, 
the use of differentiation-inducing factors causing MSCs to form neo-cartilage cells might be 
needed- However, these factors require extensive culture times. In future studies, we will try 
to develop artificial tracheas that are stronger than the native ones without using 
differentiation-inducing factors.  
Nevertheless, our study provides basic information on the formation of structures by human 
cell spheroids using a bio-3D printing system. This approach may lead to the production of 




This study optimized the culture conditions and cell combinations used to produce scaffold-
free structures with a bio-3D printing system and generated scaffold-free trachea-like tubes to 
replace the epithelium and capillaries lost because of surgical resection of rat tracheas. These 
engineered structures could represent a significant step towards the clinical application of 
bioengineered organs. 
 
5. Experimental Section 
5.1. Experimental design 
This study describes the formation of artificial tracheas. To make such tracheas with a ladder 




form a ladder structure. The cartilaginous tubes consisted of chondrocytes with or without 
MSCs and HUVECs. The fibrous tubes consisted of fibroblasts with or without MSCs and 
HUVECs. Combinations of different cells types were seeded into micro-wells to form the 
spheroids used to construct the multicellular tubes. Trachea-like tubes with ladder structures 
were made by stacking alternating tube types using a bio-3D printing system (Regenova; 
Cyfuse, Tokyo, Japan). Cartilaginous tubes, fibrous tubes and trachea-like tubes were cultured 
for 35 days in vitro and then analyzed to select the one with the most favorable values of 
stiffness and elasticity. The chosen type was transplanted into rats, replacing a section of the 
native trachea (Figure 8). 
 
5.2. Cell culture  
NHDFs (CC-2509; Lonza, Inc., Walkersville, MD, USA) were grown in fibroblast cell 
growth medium supplemented with human fibroblast growth factor-beta (hFGF-β), insulin, 
fetal bovine serum (FBS), and gentamicin/amphotericin-B (FGM2 Bullet Kit; Lonza, Inc., 
Walkersville, MD, USA). NHACs (CC-2550; Lonza, Inc., Walkersville, MD, USA) were 
grown in chondrocyte growth medium containing R3-insulin-like growth factor-1 (R3-IGF-1), 
human recombinant fibroblast growth factor-beta (hrFGF-β), transferrin, insulin, FBS, and 
gentamicin/amphotericin-B (CGM Bullet Kit; Lonza, Inc.). HUVECs (C2517A; Lonza, Inc., 
Walkersville, MD, USA) were grown in endothelial cell growth medium containing human 
epidermal growth factor (hEGF), vascular endothelial growth factor (VEGF), R3-insulin-like 
growth factor-1, ascorbic acid, hydrocortisone, hFGF-β, heparin, FBS, and 
gentamicin/amphotericin-B (EGM-2 Bullet Kit; Lonza, Inc.). Human bone marrow-derived 
MSCs (PT-2501; Lonza, Inc., Walkersville, MD, USA) were grown in mesenchymal stem cell 
growth medium (PromoCell GmbH, Heidelberg, Germany). All media were supplemented 




All cell lines were cultured on 150 mm tissue culture dishes (TPP, Trasadingen, Switzerland), 
and maintained in a humidified cell culture incubator at 37 °C under a 5% CO2 atmosphere. 
 
5.3. Preparation of multicellular spheroids  
Cell cultures were washed with phosphate buffered saline solution (PBS; Wako, Osaka, 
Japan), treated for 3 min with 0.25% trypsin (Nacalai Tesque, Kyoto, Japan), and centrifuged 
at 166 x g for 5 min. The resulting pellets were resuspended in each cell-type-specific 
medium. Afterward, we classified the chondrocyte- and fibroblast-based spheroids into seven 
and four groups, respectively, depending on the cell ratio (groups C-I – C-V; and groups F-I – 
F-IV; see Table S1 details). The mix rate of fibroblast cellular suspensions was matched with 
that of the cartilaginous tubes. Cell mixtures were plated at 2 × 104 cells/100 μL in a well of 
ultra-low adhesion, round-bottom, 96-well plates (Sumitomo Bakelite, Tokyo, Japan) and 
cultured for 48 h to generate cell spheroids.  
 
5.4. Bio-3D printing 
Three-dimensional printing data were prepared using the Cyfuse’s software for 16-level 
tubular models of cartilaginous, fibrous, and trachea-like tubes, requiring 388 spheroids each. 
The model of the trachea-like tubes consisted of two spheroid kinds; the first 2-level ring 
model consisted of group F-IV spheroids (F-IV ring) and the second 2-level ring model 
consisted of group C-IIIa spheroids (C-IIIa ring), this ring combination was repeated four 
times. Nine-by-nine needles (Kenzan; Cyfuse) were positioned to act as a temporary scaffold 
during spheroid agglutination. The needles were made of stainless steel with diameters of 170 
μm and pitches of 400 μm; a hole was left at the center of the scaffold. As described 
previously, the bio-3D printer (Cyfuse) made the tubular structures automatically, using the 
spheroids in the plates. Briefly, it picked up spheroids by vacuum through a suction nozzle 




the designed depths of the needles. In the present study, smaller spheroids were difficult to 
handle with the robotic nozzle, so the spheroid size was set accordingly. A total of 388 
spheroids were used to create the 3D tubular shape according to pre-designed 3D data (Figure 
8). The time required for the placement of the 16-level structures was approximately 1.5 h. 
 
5.5. Maturation of tubular structures 
The 3D-printed, tubular structures in the needle arrays were cultured with proper medium 
flow (200 mL/h) in a bioreactor (Figure 8) inside a humidified cell culture incubator at 37 °C 
under 5% CO2 for 7 days, at this time, the 3D shapes were self-sustaining, and the needle 
arrays were removed. The structures were transferred to 1.7 mm outer diameter plastic 
catheters (TERUMO, Tokyo, Japan). Further culturing was enforced with the proper medium 
flow (200 mL/h) in a bioreactor for 28 days with media changes every 3–4 days (Figure 8). 
The flow speed was chosen to avoid structural damage due to shear stress. The media ratio for 
cartilaginous tubes was set at 1:1 CGM:EGM2, for fibrous tubes at 1:1 FGM2:EGM2, and for 
trachea-like tubes at 1:1:1 CGM:FGM2:EGM2. 
 
5.6. Morphological and biomechanical assessment  
On the 35th day of culture, we measured the wall thickness, outer diameter, and length of the 
3D-printed tubular structures (all groups, N = 3–5 per group) and segments of 4 cartilage 
rings of 9-week-old male F344/Jcl rat cervical tracheas (N=4; CLEA, Tokyo, Japan) using a 
machine vision system (Gellex International, Tokyo, Japan). To measure pulling force, all 
structures were tested according to uniaxial tension (DMT, Ann Arbor, USA). Briefly, small, 
stainless steel pins served as grips for each individual structure. The structures were pulled in 
tension-to-failure at a rate of 50 μm/sec. Maximum loading forces were calculated and UTS 
were calculated from the pulling force by dividing the failure load by the cross-sectional area 





5.7. Biochemical analysis 
Cartilaginous tubes consisting of all spheroid groups (N = 3–5), fibrous tubes consisting of 
group F-IV spheroids (N = 3), trachea-like tubes (N = 3), and native rat tracheas (N = 3) were 
digested in papain (P4762-25MG; Sigma-Aldrich, St. Louis, MO, USA) solution (250 μg/ml 
in 20 mM sodium phosphate, pH 6.5, containing 2 mM dithiothreitol and 1 mM 
ethylenediaminetetraacetic acid (EDTA)) for 24 h at 65 °C. GAG content was measured using 
a Blyscan kit (Biocolor, Belfast, Northern Ireland), and the relative cell number was 
determined by quantification of total DNA using Quant-iT Assay kits (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s protocol. 
 
5.8. Histology and immunohistochemistry 
The structures were fixed in 10% masked formalin, (Japan Tanner Corporation, Osaka, Japan) 
embedded in paraffin, overnight, and sectioned along axial planes at 4 μm. Additionally, the 
trachea-like tubes were sectioned along vertical planes. Mounted tissue sections were 
deparaffinized, rehydrated and stained with hematoxylin-eosin to visualize cellular 
organization. The deposition and distribution of collagenous fiber and the main ECM 
component were determined by Masson’s trichrome staining. Fast Green and Picrosirius Red 
dual staining (0.1% Fast Green FCF and 0.2% Direct Red 80 in picric acid) was used to 
visualize the deposition and distribution of collagenous and non-collagenous matrix 
components by light microscopy (Aperio ImageScope; Leica Biosystems, Wetzlar, Germany). 
Polarized light images of samples stained with Picrosirius Red were acquired by inverted 
microscopy. A linear polarizer was positioned between the light source and the specimen, and 
the analyzer between the specimen and the camera. Prior to image acquisition, the analyzer 
was rotated to obtain the maximum light diminishment. Small collagen I and III fibers 




Alcian blue staining and light microscopy were used to visualize the deposition and 
distribution of GAG. Immunohistochemistry was performed using the Leica Bond III 
autostainer (Leica Biosystems) according to the manufacturer’s protocols using the following 
primary antibodies: collagen II (1:200, rabbit polyclonal, plcab; Abcam, Cambridge, UK), 
collagen IV (1:50, mouse monoclonal, M0785; Dako, Glostrup, Denmark), CD31 (1:500, 
rabbit monoclonal, bs-195 R; Bioss, Boston, MA, USA), pan-cytokeratin (1:150, mouse 
monoclonal, ab7753; Abcam). Primary antibodies were detected using a Bond Polymer 
Refine Detection Kit with 3,3′-diaminobenzidine as a chromogen (DS9800; Leica Biosystems 
Newcastle Ltd, UK). All immunohistochemistry images were acquired using a light 
microscope (Aperio ImageScope; Leica Biosystems). 
 
5.9 Animal model 
5.9.1. Implantation of trachea-like tubes in rats 
Three 9-week-old rats were used for this experiment. Four rings of each cervical trachea were 
dissected through a median cervicotomy (Figure 7a) and replaced with trachea-like tubes 
(Figure 7b) supported by silicon stents (7 mm long and 1.7 mm outer diameter; Kenis, Osaka, 
Japan). The rats were anesthetized with isoflurane (4%), and ketamine hydrochloride (85 
mg/kg; Sankyo, Tokyo, Japan) maintained with isoflurane (2%). Proximal and distal end-to-
end anastomoses were performed with 7-0 polypropylene interrupted sutures. The stent was 
secured with additional sutures, and the cervical incision was closed. Because the transplanted 
cells were human, the rats were bred under immunosuppression management with tacrolimus 
(0.5 mg/kg Prograf; Astellas Pharma Inc., Tokyo, Japan) and intratracheal secretion 
management with atropine sulfate (0.05 mg/kg; Wako Pure Chemical Industries, Ltd., Osaka, 
Japan) hypodermically once a day. At the end of this experiment, the wound was re-opened, 
both ends of the trachea-like tube were clamped, and the tube was removed. The animals were 





5.9.2. Animal care 
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was 
approved by the Institutional Animal Care and Use Committee of Nagasaki University 
(Approval number 1607261327). All efforts were made to minimize suffering. 
 
5.10. Statistical analysis 
Data are reported as means ± standard deviation (SD). One-way analysis of variance 
(ANOVA) was used to analyze the thickness, length, tensile strength, and GAG content in 
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Figure 1. Macroscopic analysis of cartilaginous tubes. 
(a–g) Images of cartilaginous tubes from the indicated groups: C-I (a), C-II (b), C-IIIa (c), C-
IIIb (d), C-IIIc (e), C-IV (f), C-V (g). Each hash mark on the ruler represents 0.5 mm. (h, i) 
Structure thickness (h) and length (i) of the cartilaginous tubes. (j, k) Mechanical analysis of 
the cartilaginous tubes expressed by the maximum load at failure (j) and ultimate tensile stress 
(UTS) during uniaxial testing (k). (l-n) Biochemical analysis of the cartilaginous tubes. GAG 
content (l), DNA content (m), and GAG normalized to DNA in harvested samples (n). Data 
represent means ± SD. * P < 0.05, ** P < 0.01 
 
Figure 2. Histological and immunohistological analysis of cartilaginous tubes.  
Cross-sections of cartilaginous tubes stained with Alcian blue (a, e, i, m, q, u, y). 
Immunohistological staining with anti-collagen II (b, f, j, n, r, v, z), anti-collagen IV (c, g, k, o, 
s, w, aa), or anti-CD31 antibodies (d, h, l, p, t, x, and bb). Group C-I (a–d), group C-II (e–h), 
group C-IIIa (i–l), group C-IIIb (m–p), group C-IIIc (q–t), group C-IV (u–x), and group C-V 
(y–bb). Scale bars = 300 μm. 
 
Figure 3. Macroscopic analysis of fibrous tubes. 
(a–d) Images of fibrous tubes from the indicated groups: F-I (a), F-II (b), F-III (c), F-IV (d). 
Each hash mark on the ruler represents 0.5 mm. (e, f) Structure thickness (e) and length (f) of 
fibrous tubes. (g, h) Mechanical analysis of cartilaginous tubes expressed by the maximum 
load at failure (g) and ultimate tensile stress (UTS) during uniaxial testing (h). Data represent 
means ± SD. * P < 0.05. 
 




Cross-sections of fibrous tubes were stained with Masson’s trichrome (a, f, k, p), Fast 
Green/Picrosirius Red (b, g, l, q), or Picrosirius Red and observed using polarized light 
microscopy (c, h, m, r). Immunohistological staining with anti-collagen IV (d, i, n, and s), or 
anti-CD31 antibodies (e, j, o, and t). Group F-I (a–e), group F-II (f–j), group F-III (k–o), and 
group F-IV (p–t). Scale bars = 300 μm. 
 
Figure 5. Macroscopic analysis of trachea-like tubes. 
(a–d) Images of trachea-like tubes. Day 0 (a), day 7 with “Kenzan” (b), day 7 without 
“Kenzan” (c), and day 35 (d). Each hash mark on the ruler represents 0.5 mm. (e, f) Structure 
thickness (e) and length (f) of fibrous tubes, cartilaginous tubes, trachea-like tubes, and native 
rat trachea. (g, h) Mechanical analysis of each sample expressed by the maximum load at 
failure (g) and ultimate tensile stress (UTS) during uniaxial testing (h). (i, j, and k) 
Biochemical analysis of cartilaginous tubes. GAG content (i), DNA content (j), and GAG 
normalized to DNA in harvested samples (k). Data represent means ± SD. * P < 0.05. 
 
Figure 6. Histological and immunohistological analysis of trachea-like tubes. 
Axial planes of trachea-like tubes were stained with hematoxylin-eosin (a), Masson’s 
trichrome (b), and Alcian blue (c). Immunohistological staining with anti-collagen IV (d), 
anti-collagen IV (e), and anti-CD31 antibodies (f). (g) regions of interest magnified in (f). 
Small capillary formation is indicated with arrowheads. Scale bars = 300 μm.  
 
Figure 7. Macroscopic and microscopic findings after tracheal transplantation. 
Defects after trachea resection during the operation (a). Photograph of the surgical field after 
graft transplantation (b), day 7 (c), and day 35 (d) after transplantation (arrows: junction 
between the graft and the trachea). Vascularization, epithelialization, and collagen formation 




the trachea-like tube is within the dotted line). Histological and immunohistological staining 
with anti-CD31 antibodies showing capillary-like tube formation in the graft (f and k). 
Immunohistological staining with anti-pan-cytokeratin antibodies showing that the 
epithelialization started on day 7 and extended to day 35 (g and l; arrowheads). The staining 
area of Alcian blue (h and m; arrowheads) and collagen II (i and n; arrowheads) became 
clearer in the trachea-like tubes over time. Scale bars = 200 μm (f and k), 400 μm (g and l), 
and 700 μm (h, i, m, and n).  
 
Figure 8. The Regenova bio-3D printer system. 
Schematic illustration showing the generation process for the tubes. Step 1: spheroid 
preparation with four cell types. Step 2: Bio-3D printing by the “Kenzan” method, three tube 
types were designed. Step 3: maturation with the proper medium flow. Step 4: transplantation 
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